CN1167698C - 用作神经激肽受体拮抗剂的n-三唑基甲基哌嗪衍生物 - Google Patents

用作神经激肽受体拮抗剂的n-三唑基甲基哌嗪衍生物 Download PDF

Info

Publication number
CN1167698C
CN1167698C CNB011228261A CN01122826A CN1167698C CN 1167698 C CN1167698 C CN 1167698C CN B011228261 A CNB011228261 A CN B011228261A CN 01122826 A CN01122826 A CN 01122826A CN 1167698 C CN1167698 C CN 1167698C
Authority
CN
China
Prior art keywords
alkyl
ring
randomly
phenyl
mixing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB011228261A
Other languages
English (en)
Chinese (zh)
Other versions
CN1335316A (zh
Inventor
D
D·杰斯兰德
U·施恩
H·萨恩
R·布鲁克纳
C·艾克霍特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Publication of CN1335316A publication Critical patent/CN1335316A/zh
Application granted granted Critical
Publication of CN1167698C publication Critical patent/CN1167698C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB011228261A 2000-07-28 2001-07-10 用作神经激肽受体拮抗剂的n-三唑基甲基哌嗪衍生物 Expired - Fee Related CN1167698C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10036818.2 2000-07-28
DE10036818A DE10036818A1 (de) 2000-07-28 2000-07-28 Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten

Publications (2)

Publication Number Publication Date
CN1335316A CN1335316A (zh) 2002-02-13
CN1167698C true CN1167698C (zh) 2004-09-22

Family

ID=7650544

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB011228261A Expired - Fee Related CN1167698C (zh) 2000-07-28 2001-07-10 用作神经激肽受体拮抗剂的n-三唑基甲基哌嗪衍生物

Country Status (27)

Country Link
US (1) US6407106B1 (enExample)
EP (1) EP1176144B1 (enExample)
JP (1) JP2002053577A (enExample)
KR (1) KR100924405B1 (enExample)
CN (1) CN1167698C (enExample)
AR (1) AR028743A1 (enExample)
AT (1) ATE244716T1 (enExample)
AU (1) AU779318B2 (enExample)
BR (1) BR0103048A (enExample)
CA (1) CA2354213C (enExample)
CZ (1) CZ301695B6 (enExample)
DE (2) DE10036818A1 (enExample)
DK (1) DK1176144T3 (enExample)
DZ (1) DZ3119A1 (enExample)
ES (1) ES2201007T3 (enExample)
HU (1) HU226687B1 (enExample)
IL (1) IL144299A (enExample)
IN (1) IN191021B (enExample)
NO (1) NO323233B1 (enExample)
NZ (1) NZ513041A (enExample)
PL (1) PL210436B1 (enExample)
PT (1) PT1176144E (enExample)
RU (1) RU2288918C2 (enExample)
SK (1) SK284802B6 (enExample)
TW (1) TWI304403B (enExample)
UA (1) UA73728C2 (enExample)
ZA (1) ZA200105737B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77515C2 (en) 2002-04-04 2006-12-15 Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity
ATE384053T1 (de) * 2002-04-26 2008-02-15 Lilly Co Eli Triazolderivate als tachykininrezeptor- antagonisten
EP1501808B1 (en) * 2002-04-26 2008-07-02 Eli Lilly And Company Tachykinin receptor antagonists
EP1638944A1 (en) * 2003-06-12 2006-03-29 Eli Lilly And Company Tachykinin receptor antagonists
US20070082905A1 (en) * 2005-05-27 2007-04-12 De Vries Michiel H Pharmaceutical compositions comprising n-triazolymethyl-piperazine compounds and methods of using same
JP4860696B2 (ja) * 2005-07-25 2012-01-25 エフ．ホフマン−ラ ロシュ アーゲー 置換トリアゾール誘導体及びそのニューロキニン３レセプターアンタゴニストとしての使用
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US9782397B2 (en) 2011-07-04 2017-10-10 Irbm Science Park S.P.A. Treatment of corneal neovascularization
EP3758688B1 (en) 2018-02-26 2024-03-27 Ospedale San Raffaele S.r.l. Nk-1 antagonists for use in the treatment of ocular pain
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
CN115184498B (zh) * 2022-07-15 2023-02-21 山东京卫制药有限公司 N-Boc-哌嗪中有关物质哌嗪的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883098A (en) 1993-11-29 1999-03-16 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
US5637592A (en) * 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
CN1072220C (zh) * 1995-05-25 2001-10-03 藤泽药品工业株式会社 作为神经激肽受体拮抗剂的1－苯甲酰基－2－(吲哚基－3－烷基)－哌嗪衍生物
GB9513118D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
AU714931B2 (en) * 1995-12-18 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives as tachykinin antagonists
KR100458346B1 (ko) * 1996-03-29 2005-06-21 듀파 인터내셔날 리서치 베 파우 피페라진및피페리딘화합물
AUPO735997A0 (en) * 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
EP0899270B1 (de) * 1997-08-27 2008-05-21 Solvay Pharmaceuticals GmbH Indolmethyl-N,N'-bisacylpiperazine als Neurokininrezeptorantagonisten
DE19824865A1 (de) 1997-08-27 1999-03-04 Solvay Pharm Gmbh Neue Harnstoffderivate
ES2162731B1 (es) * 1999-06-04 2003-02-16 Faes Fabrica Espanola De Produ Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas.

Also Published As

Publication number Publication date
CZ20011813A3 (cs) 2002-03-13
SK284802B6 (sk) 2005-11-03
NZ513041A (en) 2002-12-20
DZ3119A1 (fr) 2004-09-19
DK1176144T3 (da) 2003-10-27
EP1176144A1 (de) 2002-01-30
JP2002053577A (ja) 2002-02-19
CA2354213C (en) 2010-04-27
HU0102931D0 (en) 2001-09-28
CN1335316A (zh) 2002-02-13
SK7572001A3 (en) 2002-02-05
RU2288918C2 (ru) 2006-12-10
HK1042699A1 (en) 2002-08-23
ATE244716T1 (de) 2003-07-15
DE50100358D1 (de) 2003-08-14
HUP0102931A3 (en) 2003-07-28
BR0103048A (pt) 2002-04-02
ES2201007T3 (es) 2004-03-16
AU779318B2 (en) 2005-01-13
NO20013709L (no) 2002-01-29
EP1176144B1 (de) 2003-07-09
US20020065276A1 (en) 2002-05-30
DE10036818A1 (de) 2002-02-07
PT1176144E (pt) 2003-11-28
IL144299A (en) 2004-08-31
TWI304403B (en) 2008-12-21
KR100924405B1 (ko) 2009-10-29
HUP0102931A2 (hu) 2002-11-28
KR20020010482A (ko) 2002-02-04
AR028743A1 (es) 2003-05-21
US6407106B1 (en) 2002-06-18
HU226687B1 (en) 2009-06-29
NO323233B1 (no) 2007-02-05
ZA200105737B (en) 2002-01-22
NO20013709D0 (no) 2001-07-27
CA2354213A1 (en) 2002-01-28
UA73728C2 (en) 2005-09-15
IN191021B (enExample) 2003-09-13
PL210436B1 (pl) 2012-01-31
CZ301695B6 (cs) 2010-05-26
AU5767501A (en) 2002-01-31
PL348946A1 (en) 2002-02-11
IL144299A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
CN1079796C (zh) 新的N－7－杂环基－吡咯并[2,3－d]嘧啶及其应用
CN1167698C (zh) 用作神经激肽受体拮抗剂的n-三唑基甲基哌嗪衍生物
JP2983296B2 (ja) 新規なｎ−アミノアルキルフルオレンカルボキサミド；新規な種類のドーパミンリセプタ亜型特異性リガンド
CN1330652A (zh) 用作5HT2C激动剂的2,3,4,4a－四氢－1H－吡嗪并(1,2－a)喹喔啉－5(6H)酮衍生物
JP3176935B2 (ja) ドーパミンリセプタサプタイプ特異性リガンドとしてのｎ―アミノアルキルジベンゾフランカルボキサミド
EP1339406B1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
JPH07501803A (ja) ５−ｈｔ１ａ拮抗物質としてのピペラジン誘導体
US4870085A (en) Tryptamine derivatives active on central nervous system
CN1195741C (zh) 嘧啶酮化合物,包含该化合物的药物组合物以及制备该化合物的方法
CN1429200A (zh) 邻氨基苯甲酸酰胺及其作为药物的应用
JP2023554282A (ja) 置換ピペリジノ化合物及び関連する治療方法
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
MXPA01011534A (es) Metodos de preparar y utilizar n-desmetilzopiclona.
CN1234023A (zh) 作为多巴胺d2激动剂和5ht1a的配位体的4－氨基乙氧基吲哚
CN1050835C (zh) 1,5－苯并二氮杂衍生物、其制备方法及其药物用途
CN1507437A (zh) 具有5－羟色胺5－ht1a活性的支链金刚烷基及降金刚烷基芳基－与芳烷基－哌嗪
CN1096459C (zh) (r)－5－溴－n－(1－乙基－4－甲基六氢－1h－1,4－二氮杂䓬－6－基)－2－甲氧基－6－甲胺基－3－吡啶羧酰胺,其制备方法及含有该化合物的医药组合物
CN1156454A (zh) N-取代的3-氮杂双环[3，2，0]庚烷衍生物及其制备方法和应用
EP2294068A1 (fr) DERIVES DE 1,3-DIHYDRO-2H-PYRROLO(3,2-b) PYRIDIN-2-ONE, LEUR PREPARATION ET LEURS APPLICATIONS EN THERAPEUTIQUE
JPH10500674A (ja) ５ｈｔ▲下１ａ▼および５ｈｔ▲下１ｄ▼拮抗薬含有組成物
CN101321765A (zh) 可用作vr1受体拮抗剂的苯并吡喃酮衍生物
CN1867548A (zh) 3－氮杂双环[3.1.0]己烷衍生物的制备
CN1108290C (zh) 新的尿素衍生物
CN1168728C (zh) 吡咯并异喹啉和四氢吡咯并异喹衍生物及其作为5-ht7受体介体的应用
JP2008526712A (ja) Ｏｒｌ−１受容体用の置換されたインドールリガンド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040922

Termination date: 20120710